INTRODUCTION
============

The gut microbiota provides an intestinal biological barrier against pathogens and has a pivotal role in the maintenance of intestinal homeostasis and modulation of the host immune system \[[@b1-ce-2015-117]\]. The specific changes in the composition of gut microbiota, termed dysbiosis, have been associated not only with many gastrointestinal (GI) diseases but also with metabolic diseases, autoimmune diseases, allergic disorders, and neuropsychiatric disorders \[[@b2-ce-2015-117]\]. Restoring a healthy microbial community is therefore a promising therapeutic strategy for diseases related with gut dysbiosis \[[@b3-ce-2015-117]\]. Fecal microbiota transplantation (FMT), also called stool/fecal transplantation or fecal bacteriotherapy, is the infusion or engraftment of liquid filtrate feces from a healthy donor into the gut of a recipient to cure a specific disease \[[@b4-ce-2015-117]\]. The concept of FMT for treatment of human GI disease was described approximately 1,700 years ago by a Chinese medical scientist named Ge Hong \[[@b5-ce-2015-117]\]. At that time, he orally administered human fecal suspension to treat patients who had food poisoning or severe diarrhea. Borody et al. \[[@b4-ce-2015-117]\] and Brandt et al. \[[@b6-ce-2015-117]\] noted that FMT may have been first used in veterinary medicine by the Italian anatomist Fabricius Aquapendente in the 17th century. It was first reported in the English language by Eiseman et al. \[[@b7-ce-2015-117]\], who used fecal enemas to treat pseudomembranous colitis in 1958. Recently, FMT is becoming interesting with its effectiveness in treating refractory and recurrent *Clostridium difficile* infection (CDI) and the possibilities for treating other diverse conditions \[[@b8-ce-2015-117]\]. We review the efficacy of FMT used in treating a variety of diseases and preclinical conditions. In addition, we describe the methodology, criteria for donor selection and screening, and safety data.

PATHOPHYSIOLOGIC RATIONALE FOR FMT
==================================

The human gut microbiota is complex community of microorganisms, which include 100 trillion (10^14^) bacteria, quadrillion viruses, fungi, parasites, and archaea \[[@b1-ce-2015-117]\]. The "normal" gut microbiota consists of 500 to 1,000 species that belong to only a few bacterial phyla \[[@b9-ce-2015-117],[@b10-ce-2015-117]\]. The most abundant bacteria in the human gut are the Bacteroidetes and Firmicutes phyla, but other bacterial species mostly belong to members of the phyla Actinobacteria, Fusobacteria, Proteobacteria, Verrucomicrobia, and Cyanobacteria \[[@b9-ce-2015-117],[@b10-ce-2015-117]\]. Microbial colonization of the human gut begins during birth. Each individual has his or her own specific gut microbiota, of which the composition is influenced by various environmental factors, including diet, lifestyle, the use of antibiotics and hygiene preferences \[[@b11-ce-2015-117]\]. It is essential for several aspects of host biology, including the metabolism of indigestible polysaccharides, production of essential vitamins, development and differentiation of the host's intestinal epithelium and immune system, maintenance of tissue homeostasis, and protection against the invasion of pathogens \[[@b11-ce-2015-117]\].

Gut dysbiosis is associated with various diseases, including CDI, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), metabolic syndrome, obesity, types 1 and 2 diabetes, atopy, multiple sclerosis, autism, colorectal cancer, etc \[[@b3-ce-2015-117]\]. The protective effect of normal gut flora on CDI is well recognized \[[@b12-ce-2015-117]\]. Among several factors causing gut dysbiosis, the use of drugs, particularly antibiotics, is the most important inciting factor \[[@b13-ce-2015-117]\]. Antibiotics affect both the overall size of the gut bacterial community and the composition of the community, producing an environment that allows germination of *C. difficile* spores and expansion of the pathogen \[[@b12-ce-2015-117]\]. FMT restores gut microbiota diversity via the infusion of donor feces into the GI tract of a patient with CDI. Khoruts et al. \[[@b14-ce-2015-117]\] used molecular approaches to characterize the bacterial composition of the colonic microbiota before and after FMT in a patient with CDI. Before FMT, the patient's residual colonic microbiota was deficient in members of the normally dominant phyla, Bacteroidetes and Firmicutes. By 2 weeks after FMT, the recipient's fecal bacteria composition resembled the donor's and was dominated by *Bacteroides* spp. strains and an uncharacterized butyrate-producing bacterium. These changes were accompanied by symptom resolution and were long lasting. The suggested mechanisms are following: (1) prevention of colonization by toxigenic *C. difficile* through competition for a limited amount of nutrients; (2) direct inhibition of *C. difficile* growth and its toxigenic activity; (3) modulation of metabolites and transformation of bile acids, which indirectly impairs the life cycle of *C. difficile*; (4) physiologic cross talk between the normal flora and the host immune system, resulting in a regulated immune response that may prevent colonization by *C. difficile* and its recurrence \[[@b15-ce-2015-117]\].

Although no definitive pathogen has been detected as the etiologic factor of IBD and a definite infectious cause cannot be considered alone, many studies have investigated a disturbance of the intestinal microbiota as a contributing factor to the pathogenesis of IBD \[[@b16-ce-2015-117]\]. Gut dysbiosis in IBD is characterized by a decreased diversity at the species level, with decreases in the Bacteroides phylum and the Lachnospiraceae group within the Firmicutes phylum and a relative increase in proinflammatory bacteria such as Proteobacteria and Actinobacteria \[[@b17-ce-2015-117],[@b18-ce-2015-117]\]. In addition, a decrease in a butyrate-producing bacterium, which is important in intestinal health, has been observed in patients with IBD \[[@b16-ce-2015-117],[@b19-ce-2015-117]\]. In IBD, abnormal microbial colonization of the GI tract may be the origin of excessive or dysregulated immune response, resulting in chronic inflammation and the development of mucosal lesions \[[@b18-ce-2015-117]\]. However, it is still unclear whether dysbiosis itself causes IBD or if it represents an epiphenomenon due to microbial alterations as a consequence of the disease \[[@b19-ce-2015-117]\]. Several studies reported that FMT may be a promising approach for the management of diseases associated with gut dysbiosis, including IBD \[[@b20-ce-2015-117]\].

CLINICAL APPLICATIONS
=====================

*C. difficile* infection
------------------------

In 1978, *C. difficile* was first identified as the cause of pseudomembranous colitis \[[@b21-ce-2015-117]\]. Because of high rate of recurrence (15% to 30%), patients with CDI have higher health-care burden \[[@b8-ce-2015-117]\]. In the past few decades, FMT has received considerable attention because of a convincing clinical trial of treatment of recurrent CDI. The first randomized controlled trial (RCT) of FMT for 43 patients with recurrent CDI compared FMT administered via nasoduodenal tube after 4 to 5 days of oral vancomycin with 14 days of continued vancomycin alone and with 14 days of vancomycin plus bowel lavage \[[@b22-ce-2015-117]\]. Symptoms resolved within 3 months in 81% of patients receiving FMT, in 31% of those receiving vancomycin alone, and in 23% of patients receiving vancomycin plus bowel lavage. The study was terminated early because FMT was more than twice as effective in resolving symptoms as antibiotics alone. The second RCT compared two FMT treatment approaches, via nasogastric tube and via colonoscopy, in 20 patients \[[@b23-ce-2015-117]\]. Symptoms resolved completely for 70% of patients after single FMT, and the overall cure rate was 90% after retreatment; the difference between treatment approaches was not significant (60% in the nasogastric tube group and 80% in the colonoscopy group; *p*=0.63). However, this study was unblinded and did not include a non-FMT control group. The first systematic review published in 2011 included 317 patients with recurrent CDI treated with FMT across 27 cases and reports \[[@b24-ce-2015-117]\]. Symptoms resolved in 92% of patients, 89% after a single treatment, and 5% after retreatment due to failure or relapse. A recent systematic review published in 2015 included two RCTs, 28 case-series studies, and five case reports \[[@b8-ce-2015-117]\]. The results showed that FMT was successful in 85% of recurrent CDI and 55% of refractory CDI compared with 30% to 80% success rates for medical therapies. Although FMT has a substantial effect and few short-term side effects for adults with recurrent CDI, there is insufficient evidence regarding FMT for patients with refractory CDI or for initial treatment of CDI. Considerations for future study in CDI include the need for a large, blinded RCT that would compare FMT with placebo in patients randomized after standard antimicrobial therapies, the best source and processing methods for donor stool, and the best timing for FMT after antimicrobial use. The two most recent guidelines differ about the strength of evidence supporting FMT---a European guideline stated that FMT is "strongly recommended (A-I)" after a second recurrence of CDI \[[@b25-ce-2015-117]\], whereas a guideline from the American College of Gastroenterology offered a more cautious recommendation, stating that "if there is a third recurrence after a pulsed vancomycin regimen, FMT should be considered (conditional recommendation, moderate quality evidence) \[[@b26-ce-2015-117]\]." FMT for CDI is a topic of considerable research. Despite the high success rate of FMT in treating recurrence, its wider practice is hindered by several factors, including concerns about pathogen transmission, limited viability of fresh samples, lack of reimbursement for donor screening, difficulty in stool preparation and administration, concerns about doing the procedure in the endoscopy laboratory or medical office due to odor, difficulty in convincing patients, and lack of standardized treatment regimen \[[@b23-ce-2015-117],[@b27-ce-2015-117]-[@b29-ce-2015-117]\]. Patel et al. \[[@b30-ce-2015-117]\] reported a successful outcome in two patients with recurrent CDI unresponsive to repeated courses of antibiotics who received a stool substitute, a preparation of 33 different intestinal bacteria isolated in pure culture from a single donor. Recent studies demonstrated that FMT using a frozen inoculum from carefully screened health volunteer donor is effective for treating recurrent CDI \[[@b23-ce-2015-117],[@b31-ce-2015-117]\]. The outcomes of this approach was similar with those of FMT with fresh stools, suggesting that preparation of frozen transplants can simplify the practical aspects of FMT without loss of efficacy or safety \[[@b29-ce-2015-117]\]. A more recent feasibility study used frozen fecal capsules, prepared from prescreened healthy donor for treating 20 patients with recurrent CDI \[[@b28-ce-2015-117]\]. The results showed an overall 90% rate of clinical resolution of diarrhea after one or two treatment courses. In Korea, Gweon et al. \[[@b32-ce-2015-117]\] first reported two cases of refractory pseudomembranous colitis treated with FMT in 2013. Subsequent case reports showed FMT can cure CDI complicated by acute respiratory distress syndrome \[[@b33-ce-2015-117]\], toxic megacolon by CDI \[[@b34-ce-2015-117]\], and CDI in a patient colonized by vancomycin-resistant enterococcus \[[@b35-ce-2015-117]\].

Inflammatory bowel disease
--------------------------

FMT for IBD was first reported in 1989, with one of the authors himself experiencing severely active ulcerative colitis (UC), refractory to aminosalicylates and corticosteroids \[[@b36-ce-2015-117]\]. He performed transplantation of a healthy donor stool by retention enema. Symptoms disappeared for 6 months after FMT, and active inflammation was not detected at follow-up biopsy sampling of the colon. Another preliminary case report of FMT enema showed significant clinical improvements in several GI conditions including constipation, IBS, UC, and Crohn disease (CD) \[[@b37-ce-2015-117]\]. These studies were followed by anecdotal reports and small case series in patients with IBD and combined CDI, showing a beneficial effect of FMT \[[@b4-ce-2015-117],[@b38-ce-2015-117],[@b39-ce-2015-117]\]. The first systematic review was published in 2012 and included 41 patients with IBD (27 UC, 12 CD, and two unclassified) treated with FMT via enema, colonoscopy, or nasojejunal tube \[[@b40-ce-2015-117]\]. Among all the patients, 15 patients received FMT for treatment of combined CDI and 26 patients received FMT for treatment of IBD. The majority of the patients for IBD treatment experienced a reduction of symptoms (19/25), cessation of IBD medications (13/17), and endoscopic and histologic disease remission (15/24). However, the high rates (63%) of remission in this review may be due to publication bias because the study did not include a complete clinical overview of patients achieving disease remission. This review was limited to the nine small case series/reports available at the time. A second systematic review of 111 patients reported a "success rate" of 77.8% for adult IBD patients \[[@b41-ce-2015-117]\]. However, this study also had several methodological limitations; notably, the clinical outcomes after FMT were assessed by treatment success rate and not by using any other, more validated measures. A recent systematic review and meta-analysis analyzed 18 studies (nine cohort studies, eight case studies, and one RCT) on FMT that included 122 patients with IBD (79 UC, 39 CD, and four unclassified) \[[@b20-ce-2015-117]\]. In this study, clinical remission after FMT was achieved in 54 (45%) of 119 patients. However, the pooled estimate for achieving clinical remission was 36.2%, when the case series were excluded to minimize publication bias. In subgroup analyses, the pooled estimates were 22% in UC, 60.5% in CD, and 64.1% in young patients (age 7 to 20 years), respectively. Although it might appear that FMT is more effective in CD or younger patients, the patient populations were significantly heterogeneous, limiting the applicability of these conclusions.

Recently, the first RCTs evaluating the efficacy of FMT in UC were reported \[[@b42-ce-2015-117],[@b43-ce-2015-117]\]. In the study reported by Moayyedi et al. \[[@b42-ce-2015-117]\], 75 patients with mild to moderate UC were randomized to weekly FMT or placebo (water) via retention enema for 6 weeks. The primary end point was remission of UC, defined as a Mayo score of \<3 with complete mucosal healing at week 7. Remission was achieved in 24% of patients receiving FMT and 5% with placebo, and the difference in remission was statistically significant. In addition, stool from patients receiving FMT developed an increase in microbial diversity compared with those given placebo. The second study enrolled 50 patients, also with mild to moderate UC, and randomized patients to either donor stool or autologous FMT (infusion of their own stool as placebo) delivered via nasoduodenal tube at baseline and again 3 weeks later \[[@b43-ce-2015-117]\]. The primary end point was clinical remission combined with ≥1-point decrease in the Mayo score at week 12. Only 37 patients completed the primary end point assessment. Clinical remission was achieved in 30.4% of patients receiving FMT and 25% with autologous FMT, but the difference was not statistically significant. Nevertheless, the microbiota profile of responders of FMT group was similar to that of their respective donors, whereas nonresponders did not show the same trend. Both studies were terminated by their respective data and safety monitoring boards due to futility in reaching primary efficacy point.

Studies investigating the therapeutic efficacy of FMT in CD have been limited to small, uncontrolled series with varying response rates. It has been reported that CD is less likely to respond to FMT compared with UC \[[@b44-ce-2015-117]\]. Although a few case series demonstrated successful outcomes after single infusion \[[@b45-ce-2015-117],[@b46-ce-2015-117]\], multiple treatment courses are required in the most of the patients with CD \[[@b47-ce-2015-117]\]. A recent study from China reported the results of single FMT through the mid-gut in 30 patients with refractory CD \[[@b48-ce-2015-117]\]. The rates of clinical improvement and clinical remission at the first month were 86.7% (26/30) and 76.7% (23/30), respectively. In addition, the body weights of the patients increased significantly at 3-month assessment point after FMT. A number of RCTs of FMT for IBD, at least four of which are for CD, are registered on clinicaltrials.gov (accessed 2015 Sep 10) and now underway to further characterize treatment efficacy and safety. Taken together, FMT is not nearly as effective in IBD as it is in CDI, suggesting that IBD is a more complicated disease with a complex pathologic interplay among genetic, environmental, immunologic, and gut microbial factors. In future clinical trials, various clinical conditions, such as patients' clinical characteristics, concomitant medications, timing of FMT, and dosage or frequency of FMT, should be considered.

Functional GI disorders
-----------------------

The current working hypothesis is that abnormal microbiota activates mucosal innate immune responses that increase epithelial permeability, activates nociceptive sensory pathways, and dysregulates the enteric nervous system \[[@b49-ce-2015-117]\]. In contrast to IBD, the role of the microbiota in the development of IBS only recently has been considered, but early stage results have been encouraging. The rationale for microbiota-directed interventions for treatment of IBS seems weaker than in IBD, but is emerging \[[@b50-ce-2015-117]\]. Although alterations in immunity, motility, and the brain-gut axis have been implicated in disease pathogenesis, the role of the intestinal microbiota are increasing, and numerous studies have demonstrated significant differences from normal in the intestinal flora of functional gastrointestinal disorder (FGID) with those of the healthy population and between types of FGID \[[@b51-ce-2015-117]\]. A recent study reported a global and deep molecular analysis of fecal samples from 62 IBS patients and 46 healthy controls and confirmed a statistically significant difference in their intestinal microbiota composition. IBS patients had a significant decrease in the numbers of Bacteroidetes and *Bifidobacterium* and *Faecalibacterium* spp. and a significant increase in Firmicutes \[[@b52-ce-2015-117]\]. This alteration of intestinal microbiota in IBS patients has been linked to immune dysfunction and altered neurological function such as increased anxiety and decreased pain threshold, suggesting that restoration of normal intestinal homeostasis via FMT may result in symptomatic improvement \[[@b51-ce-2015-117]\]. Pinn et al. \[[@b53-ce-2015-117]\] reported the efficacy of FMT for the treatment of IBS. They treated 13 patients (nine with IBS with diarrhea, three with IBS with constipation, and one with IBS with a mixed bowel pattern) and observed them for an average of 11 months. Resolution or improvement of symptoms was reported in 70%, including abdominal pain (72%), bowel habit (69%), dyspepsia (67%), bloating (50%), and flatus (42%). In a case series of 45 patients with chronic constipation who were treated with FMT via colonoscopy followed by a single fecal enema infusion the next day, 40 (89%) reported symptomatic relief soon after FMT, with 18 patients reporting normal defecation during the follow up of 9 to 19 months \[[@b54-ce-2015-117]\]. Although preliminary studies are promising, RCTs are needed to determine if FMT truly is an effective treatment modality for IBS or chronic constipation.

Non-GI disorders
----------------

FMT can also be used to treat diseases other than GI disorders in which the gut microbiota is disturbed. There are preliminary reports on the use of FMT therapy in a wide range of disorders including Parkinson's disease, fibromyalgia, chronic fatigue syndrome, myoclonus dystonia, multiple sclerosis, obesity, insulin resistance, metabolic syndrome, and childhood regressive autism ([Table 1](#t1-ce-2015-117){ref-type="table"}) \[[@b2-ce-2015-117]\]. Vrieze et al. \[[@b55-ce-2015-117]\] performed RCT of FMT in 18 male patients with metabolic syndrome. Patients who received fecal microbiota infusion from lean male donors reported a marked increase in insulin sensitivity and levels of butyrate-producing intestinal microbiota after 6-week infusion, whereas no significant changes were seen in the control group.

FMT PROCEDURES
==============

FMT carries the possibility of transmitting infectious agents, and therefore, rigorous screening tests are recommended to reduce such risk ([Fig. 1](#f1-ce-2015-117){ref-type="fig"}) \[[@b56-ce-2015-117]\]. Once a donor is selected, blood and fecal samples must be tested for pathogens. Current guidelines by an FMT workgroup in the United States \[[@b57-ce-2015-117]\] recommend using a donor questionnaire that is similar to current protocols for screening blood donors. Donor exclusion criteria are shown in the "history" part of [Fig. 1](#f1-ce-2015-117){ref-type="fig"}. The donors may be chosen from family members, intimate partners, friends, or unrelated volunteer. Intimate partners have the advantage of shared environmental risk factors, which may minimize the risk of infection transmission \[[@b57-ce-2015-117]\]. In addition, maternal-line first-degree relatives may have the advantage of sharing the greatest number of microbial species in their intestinal microbiota with the recipient; thus, adaptive immune elements in the mucosal immune system (e.g., antigen-specific antibody) might be more tolerant of the microbiota from such donors \[[@b57-ce-2015-117]\]. The first systematic review of 317 patients with recurrent CDI reported that FMT from a related donor showed a slightly higher resolution rate (93%) compared with unrelated donor (84%) \[[@b24-ce-2015-117]\]. In addition, the difference in sex between donor and recipient had little impact on disease remission. However, these findings are still lacking evidence because recent meta-analysis did not show this difference \[[@b58-ce-2015-117]\]. Unrelated volunteer donors may have an advantage when FMT is used to treat diseases in which genetics play a contributing factor, such as IBD \[[@b59-ce-2015-117]\]. With regard to the preoperative preparation, recipients usually take large-volume bowel preparation regardless of the routes of administration. In some protocols, GI motility inhibitors such as loperamide are given to optimize retention of fecal microbiota contents \[[@b19-ce-2015-117]\]. In addition, proton pump inhibitors should be administered to recipients who undergo FMT via upper GI route. The ideal fecal amount to be used for FMT has not been standardized. Practitioners who regularly perform FMT favor 50 to 60 g of 250 to 300 mL diluent, respectively \[[@b56-ce-2015-117]\]. [Fig. 2](#f2-ce-2015-117){ref-type="fig"} shows FMT procedures. A specimen of stool is suspended in tap or bottled water, milk, or nonbacteriostatic saline solution, although the latter is presumed to be less likely to affect the microbiota of donor stool \[[@b59-ce-2015-117]\]. Donor stool is then homogenized either by hand stirring and shaking or using a mechanical blender. After suspension with the diluent, the mixture is filtered through a gauze or coffee filter or strained through a steel strainer to remove larger particulates \[[@b56-ce-2015-117]\]. Administration of donor feces can be performed via the lower GI route, including colonoscopy, flexible sigmoidoscopy, rectal tube, or retention enema and/ or via the upper GI route such as nasogastric/nasointestinal tubes or gastroduodenoscopy. There is no definitive evidence for choosing any one modality over the other. Colonoscopic FMT is usually safe, well-tolerated, easily performed, and has the advantage of allowing examination of the entire colon; however, it must be selected carefully in patients with severe colitis and significant colonic distention due to a higher risk of perforation \[[@b19-ce-2015-117]\]. In such cases, retention enema and flexible sigmoidoscopy could be alternative options, but they may be difficult for some patients to retain the transplanted stool and repeated, small-volume infusions over the course of 2 to 3 days may be required. FMT via the upper GI route is easy to perform and has a low risk. However, it may be uncomfortable and have some risk of vomiting and aspiration \[[@b59-ce-2015-117]\]. In addition, it has some problems that donor stool may not be distributed throughout the entire colon and increase the risk of small intestinal bacterial overgrowth. Further studies are required to evaluate standardized and optimal route for FMT according to clinical situations.

POTENTIAL ADVERSE EVENTS
========================

FMT may be safe and well tolerated with few serious adverse events, even though it is often administered to patients with significant medical comorbid conditions \[[@b59-ce-2015-117]\]. [Table 2](#t2-ce-2015-117){ref-type="table"} shows shortterm or potential long-term adverse events. Commonly reported immediate adverse events after FMT include abdominal discomfort, bloating, flatulence, diarrhea, constipation, vomiting, and transient fever \[[@b19-ce-2015-117],[@b20-ce-2015-117]\]. Most of these symptoms are self-limiting and disappear within 2 days after FMT. However, very little information is available regarding the long-term immunologic effects of FMT, including the onset of latent infections. In addition, diseases or conditions related to changes in gut microbiota may occur, including obesity, diabetes, atherosclerosis, IBD, colon cancer, nonalcoholic fatty liver disease, IBS, asthma, and autism. Long-term follow-up data for FMT should be investigated further \[[@b59-ce-2015-117]\]. In a recent systematic review of FMT for recurrent CDI, no severe adverse events were reported \[[@b8-ce-2015-117]\]. However, several safety concerns have been raised. A further concern is that the fame of FMT may lead to patients to use a "do-it-yourself " approach, without medical control, with possibly harmful consequences \[[@b60-ce-2015-117]\]. De Leon et al. \[[@b61-ce-2015-117]\] reported a UC patient who had been quiescent for more than 20 years and developed a flare of UC after FMT. This case report cautions us in utilizing FMT to treat CDI with UC. Moreover, a recent paper reported a UC patient who suffered cytomegalovirus infection after performing FMT without donor screening \[[@b62-ce-2015-117]\]. As extracts of feces are mediators between the donor and the recipient, FMT has the potential for transmitting occult infections even when strict donor screening is performed. Possible transmission of norovirus infection through colonoscopic FMT has been reported but has not been proven definitely \[[@b63-ce-2015-117]\]; it was hypothesized that the infection could have, in one case, originated from a medical personnel participating in the procedure. Future attempts to treat CDI or alter the microbiota of patients with IBD for treatment of IBD alone should be done with caution. Prospective controlled trials of FMT in CDI and other GI diseases to evaluate safety and efficacy will help further delineate indications, risks, and benefits.

CONCLUSIONS
===========

The high success rate and safety in the short-term reported for recurrent CDI has elevated FMT as an emerging treatment modality for a wide spectrum of other conditions associated with intestinal dysbiosis. Although the role of FMT in primary and severe CDI has not been established, FMT is recommended in case of two or more recurrences of uncomplicated CDI \[[@b64-ce-2015-117]\]. However, there remain many unanswered questions regarding FMT. The US Food and Drug Administration have determined that fecal microbiota products collected from healthy individuals is a biological product and a drug, requiring an investigational new drug application. Therefore, large RCTs to support safety and efficacy are necessary. In addition to regulatory issues, various issues to be considered include donor selection and screening, standardized protocols of stool preparation and route of administration, number of infusion and quantity of infused material, recipient preparation, and long-term safety. Furthermore, microbial restoration mechanisms should be defined with recent technological advances, including improvements in sequencing and computational biology. Finally, there is a need to develop new delivery methods to improve the accessibility. In the future, convenient equipment for stool preparation and oral formulations filled with fecal suspension or freeze-dried preparations will provide less aesthetic concerns, greater convenience, and maybe higher efficacy.
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![Donor and recipient screening for fecal microbiota transplantation. IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IgM, immunoglobulin M; FMT, fecal microbiota transplantation; HIV, human immunodeficiency virus.](ce-2015-117f1){#f1-ce-2015-117}

![Fecal microbiota transplantation procedures. (A) Donor stool and normal saline (1:3) ground in a blender. (B) Fecal suspension in 50-mL syringes. (C) Infusion using colonoscopy.](ce-2015-117f2){#f2-ce-2015-117}

###### 

Disorders Associated with an Altered Intestinal Microbiota

  Gastrointestinal                                                                            Non-gastrointestinal
  ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Cholelithiasis                                                                              Arthritis
  Colorectal cancer                                                                           Asthma
  Hepatic encephalopathy                                                                      Atopy
  Idiopathic constipation^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^                       Autism^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
  Inflammatory bowel disease^[b)](#tfn2-ce-2015-117){ref-type="table-fn"}^                    Autoimmune disorder
  Irritable bowel syndrome^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^                      Chronic fatigue syndrome^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
  Familial Mediterranean fever                                                                Diabetes mellitus and insulin resistance^[b)](#tfn2-ce-2015-117){ref-type="table-fn"}^
  Gastric carcinoma and lymphoma                                                              Eczema
  Recurrent *Clostridium difficile* infection^[b)](#tfn2-ce-2015-117){ref-type="table-fn"}^   Fibromyalgia^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
                                                                                              Hay fever
                                                                                              Hypercholesterolemia
                                                                                              Idiopathic thrombocytopenic purpura^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
                                                                                              Ischemic heart disease
                                                                                              Metabolic syndrome^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
                                                                                              Mood disorders
                                                                                              Multiple sclerosis^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
                                                                                              Myoclonus dystonia^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^
                                                                                              Nonalcoholic fatty liver disease
                                                                                              Obesity
                                                                                              Oxalic acid kidney stones
                                                                                              Parkinson's disease^[a)](#tfn1-ce-2015-117){ref-type="table-fn"}^

Beneficial effect fecal microbiota transplantation (FMT) in case series;

Beneficial effect FMT in randomized clinical trials.

###### 

Short-Term or Potential Long-Term Adverse Events of Fecal Microbiota Transplantation

  Short-term adverse events   Potential long-term adverse events                        
  --------------------------- --------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abdominal discomfort        Complications of endoscopy (perforation, bleeding)        Transmission of unrecognized infectious agents that cause illness years later (e.g., hepatitis C, HIV)
  Bloating                    Adverse effects related to sedation (aspiration)          Induction of chronic diseases based on alterations in the gut microbiota (e.g., obesity, diabetes, atherosclerosis, IBD, colon cancer, nonalcoholic fatty liver disease, IBS, asthma, autism)
  Flatulence                  Transmission of enteric pathogens                         
  Diarrhea                    Peritonitis in a patient undergoing peritoneal dialysis   
  Constipation                Pneumonia                                                 
  Borborygmus                 IBD flares                                                
  Vomiting                                                                              
  Transient fever                                                                       

HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.
